In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer

In a surprising setback, the combination of two drugs—both with proven track records in liver cancer—didn't significantly extend life for newly diagnosed patients.

Pitted against Bayer’s old standard Nexavar, the combo of Exelixis’ tyrosine kinase inhibitor Cabometyx and Roche’s immuno-oncology agent Tecentriq failed to prolong patients’ lives in previously untreated hepatocellular carcinoma (HCC), the most common type of liver cancer, Exelixis said Monday.